ADMA Biologics CEO Grossman sells 147,000 shares

The transactions were reported under a Rule 10b5-1 trading plan entered into with Fidelity Brokerage Services LLC on November 14, 2025.

Available on EDGAR 11/05/2026 - 09:05 PM EST Accepted by SEC EDGAR 11/05/2026 - 09:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ADMA Biologics, Inc. President and CEO and director Adam S. Grossman exercised options for 105,000 shares on November 5, 2026, at an exercise price of $5.40 per share. He sold 147,000 common shares at $12.00 per share that day. The transactions were effected under a Rule 10b5-1 trading plan entered into with Fidelity Brokerage Services LLC on November 14, 2025. The reported stock-option position following the exercise was 585,950 shares.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Grossman Adam S

Role President and CEO

Sold 147,000 shs ($1.76M)

Approx. gross sale proceeds $1.76M

Approx. exercise cost $567K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F8	105,000	$0.00	$0.00
Exercise	Common Stock F1	105,000	$5.40	$567K
Sale	Common Stock F1, F2	105,000	$12.00	$1.26M
Sale	Common Stock F1, F2, F3, F4, F5	42,000	$12.00	$504K
Holding	Common Stock F6	--	--	--
Holding	Common Stock F7	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 585,950 contracts (Direct); Common Stock — 2,070,777 shares (Direct); Common Stock — 1,724,383 shares (Indirect, See Footnote)

Footnotes (8)

1. F1. Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
2. F2. The price reported in Column 4 is the price at which the shares were sold.
3. F3. Includes, as of the transaction date, (i) 282,529 unvested restricted stock units ("RSUs") granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
4. F4. (continued from footnote 3) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023, vesting quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
5. F5. (continued from footnote 4) and (v) 1,176,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
6. F6. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
7. F7. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
8. F8. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Key Figures

Shares acquired through option exercise: 105,000 shares Option exercise price: $5.40 per share Common shares sold: 147,000 shares +2 more

5 metrics

Shares acquired through option exercise 105,000 shares November 5, 2026

Option exercise price $5.40 per share November 5, 2026

Common shares sold 147,000 shares November 5, 2026

Sale price $12.00 per share November 5, 2026

Stock-option position following exercise 585,950 shares Reported following the November 5, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, restricted stock units ("RSUs"), net settlement upon vesting

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units ("RSUs") financial

"282,529 unvested restricted stock units ("RSUs")"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

net settlement upon vesting financial

"prior net settlement upon vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ADMA shares did Adam S. Grossman sell, and at what price?

Adam S. Grossman sold 147,000 common shares on November 5, 2026, at $12.00 per share. The two reported sale entries were 105,000 shares and 42,000 shares, and the transaction was effected under a Rule 10b5-1 trading plan entered into with Fidelity Brokerage Services LLC on November 14, 2025.

What were the terms of Adam S. Grossman's ADMA option exercise?

On November 5, 2026, Grossman exercised options covering 105,000 shares at $5.40 per share. The option was granted February 26, 2024, vested over four years, and had an expiration date of February 26, 2034.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grossman Adam S

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NEW JERSEY 07446

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2026		M		105,000(1)	A	$5.4	2,217,777	D
Common Stock	11/05/2026		S		105,000(1)	D	$12(2)	2,112,777	D
Common Stock	11/05/2026		S		42,000(1)	D	$12(2)	2,070,777(3)(4)(5)	D
Common Stock								1,143,426	I	See Footnote(6)
Common Stock								580,957	I	See Footnote(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.4	11/05/2026		M			105,000(1)	(8)	02/26/2034	Common Stock	105,000	$0	585,950	D

Explanation of Responses:

1. Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

2. The price reported in Column 4 is the price at which the shares were sold.

3. Includes, as of the transaction date, (i) 282,529 unvested restricted stock units ("RSUs") granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

4. (continued from footnote 3) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023, vesting quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

5. (continued from footnote 4) and (v) 1,176,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

6. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.

7. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

8. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

	/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact	11/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)